Excellent news for Allergy Therapeutics. Allergy Therapeutics (AGY) Announces Positive Results From Grass Ph II Study. This company is interesting because AGY provides the only ultra-short course, aluminium-free treatment containing our MPL adjuvant in the European market. Further due to the dosing regimen it could be more convenient for patients. These factors AGY says is “driving […]
This author has yet to write their bio.Meanwhile lets just say that we are proud kidsdoc1 contributed a whooping 1 entries.